About Us

Drug discovery, development, and commercialization must become faster and more efficient to address humanity’s health needs. Sumitovant embodies the bold promise of combining technology and life-sciences expertise to drive innovation.

We are a technology-driven biopharma company accelerating development and commercialization of novel therapeutics for patients with rare conditions and other serious diseases.

Diverse Portfolio

Our portfolio includes marketed products and a robust investigational pipeline addressing unmet patient needs in pediatrics, urology, oncology, women’s health, specialty respiratory and infectious diseases.

Patient-First Programs

We are next-generation biopharma innovating for patient-first outcomes through an agile approach that centers on the patient throughout.

Our Origins

Formed in 2019, Sumitovant was founded through the strategic alliance between Roivant Sciences and Sumitomo Pharma, our parent company based in Japan. Backed by Sumitomo Pharma's industry expertise and resources, Sumitovant is uniquely equipped to fuel innovation across the portfolio and to progress robust development and commercialization efforts.


Our Team

We are industry-leading experts in drug development, business, engineering, science, and technology. Together, we operate with data-driven insights, agility, and scientific rigor to advance therapies people need most.



  • Myrtle Potter

    Chief Executive Officer, Sumitovant
  • Adele Gulfo

    Chief Business Development and Commercialization Officer
  • Bill McMahon

    Chief Algorithmic Analytics Officer
  • Dan Rothman

    Chief Information Officer
  • Mi Yong Cho

    Chief People Officer
  • Tara Soni

    General Counsel
  • Sam Azoulay

    Chief Medical Officer and Head of R&D
  • Christine Ocampo

    Chief Accounting Officer
  • Atsushi Kataoka

    SVP, Finance Management

Board of Directors

  • Hiroshi Nomura

    Hiroshi Nomura

    Chief Executive Officer, Sumitomo Pharma
  • Myrtle Potter

    Myrtle Potter

    Chief Executive Officer, Sumitovant
  • Dr. Toru Kimura

    Dr. Toru Kimura

    Chief Scientific Officer, Sumitomo Pharma
  • Shigeyuki Nishinaka

    Shigeyuki Nishinaka

    Senior Executive Officer, Sumitomo Pharma
  • Matt Gline

    Matt Gline

    Chief Executive Officer, Roivant

Portfolio Companies

Urovant Sciences

Urovant Sciences is a clinical–stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.

Enzyvant Therapeutics

Enzyvant Therapeutics is focused on transformative therapies for rare, often fatal, diseases.

Myovant Sciences

Myovant Sciences is committed to addressing unmet need in women’s health and advanced prostate cancer through purpose-driven science, empowering medicines, and transformative advocacy.

Spirovant Sciences

Spirovant Sciences is focused on changing the course of cystic fibrosis and other pulmonary diseases.


Symptoms of Uterine Fibroids – Combination Therapy


Symptoms of Uterine Fibroids – Combination Therapy